Friday, 16 October 2026European Markets

LAVIDE HOLDING Stock Over 9% Down So Far On Thursday

Loading stream...

Early on Thursday morning, shares of LAVIDE HOLDING on the AEX Index experienced a sharp 9.38% drop to 23 cents at 11:23 EST. This follows the company's previously upward trend and coincided with an overall decrease of 1.11% on the AEX Index to EUR766.43. This marked the third straight day of losses for the index, potentially signaling a broader downtrend in the market.

LAVIDE HOLDING's Position

Having been established in 1998 and situated in Sluis, the Netherlands, LAVIDE HOLDING closed its last trading session at 26 cents. That is significantly lower than its 52-week high of 51 cents by a margin of 49.8%.

Analyzed Performance

The company also underperformed significantly in terms of trading volume. Only 50 shares were traded, massively contrasting with the average trading volume of 6,622 shares, a decrease of 99.244% from the usual average. Furthermore, the trading value of LAVIDE HOLDING's shares currently lags behind its moving averages. Shares are trading well below both their 50-day moving average of EUR0.28 and 200-day moving averages (both EUR0.33).

A Deeper Look

Taken as a whole, these recent movements in LAVIDE HOLDING's stock prices and their moving averages, coupled with an unusually low trading volume, could be interpreted as a sign of investor disillusionment with the company's performance and wider market trends. These market indicators suggest that before making any investment decisions, a close monitoring of LAVIDE's performance would be advisable.

More news about LAVIDE HOLDING (LVIDE.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com